REFERENCES
1. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557-65.
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
3. Do A, Zahrawi F, Mehal WZ. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nat Rev Drug Discov. 2025;24:171-89.
4. Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2023;44:14-32.
5. Banerjee M, Pal R, Pal S. Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: a network meta-analysis. Diabetes Obes Metab. 2026;28:287-95.
6. Schattenberg JM, Grønbæk H, Kliers I, et al. Proteomic signatures reflect effects of semaglutide treatment for MASH. JHEP Rep. 2025;7:101521.
7. Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
8. Newsome PN, Buchholtz K, Cusi K, et al.; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113-24.
9. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L; American Association for the Study of Liver Diseases, United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-405.
10. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
11. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78.e5.
12. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44.
13. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362-73.
14. Rosenberg WM, Voelker M, Thiel R, et al.; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704-13.
15. Petta S, Kim K, Targher G, et al. Focus on semaglutide 2.4 mg/week for the treatment of metabolic dysfunction-associated steatohepatitis. Liver Int. 2025;45:e70407.
16. Loomba R, Abdelmalek MF, Armstrong MJ, et al.; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511-22.
17. Jara M, Norlin J, Kjær MS, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31:3128-40.
18. Xiao T, Hua D, Wang Y, Lu X, Zhang C. Benchmarking large language models for cell typing in single-cell RNA-Seq. Brief Bioinform. 2025;26:bbaf677.
19. Maretty L, Gill D, Simonsen L, et al. Proteomic changes upon treatment with semaglutide in individuals with obesity. Nat Med. 2025;31:267-77.
20. Harrison SA, Bedossa P, Guy CD, et al.; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
21. Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012-24.
22. Zhou XD, Fan QY, Byrne CD, et al. Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities. Gut. 2026;75:815-25.
23. Pirola CJ, Sookoian S. Panomics in metabolic dysfunction-associated steatotic liver disease: unravelling the drivers of disease heterogeneity. Clin Mol Hepatol. 2026;32:156-69.
